Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ:AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl)…
Cel-Sci Corporation Shares Move Lower; Adam Feuerstein Tweets ‘$CVM posted results from Multikine ph3 study on clinicaltrials gov today, confirming the failure….Placebo patients lived longer. This drug is not getting approved, anywhere.’
https://twitter.com/adamfeuerstein/status/1560652668212719616
Applied Biology Sponsored Study Titled ‘Treatment for Post Acute COVID-19 Syndrome’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting; Jupiter Wellness Is A Collaborator On Study
https://clinicaltrials.gov/ct2/show/NCT05507372
Axsome’s Depression Candidate Scores FDA Nod, Stock Surges To 52-High
The FDA has approved Axsome Therapeutics Inc’s (NASDAQ:AXSM) Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for major depressive disorder (MDD) in…
Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.
Axsome Therapeutics Announced FDA Approval of AUVELITY for the Treatment of Major Depressive Disorder in Adults
Axsome Therapeutics, Inc. (NASDAQ: AXSM) today announced that the U.S.